Efanesoctocog alfa
Medication
From Wikipedia, the free encyclopedia
Efanesoctocog alfa, sold under the brand name Altuviiio, is a medication used for the treatment of hemophilia A (congenital factor VIII deficiency).[3][6]
| Clinical data | |
|---|---|
| Trade names | Altuviiio, Altuvoct |
| Other names | BIVV001; antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C13690H20958N3682O4376S136 |
| Molar mass | 311501.81 g·mol−1 |
Efanesoctocog alfa was approved for medical use in the United States in February 2023.[3][6][7][8][9]
Medical uses
Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.[3][6]
Society and culture
Legal status
In April 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Altuvoct, intended for the prevention and treatment of bleeding in people with hemophilia A caused by factor VIII deficiency.[4][10] The applicant for this medicinal product is Swedish Orphan Biovitrum.[4] Altuvoct was approved for medical use in the European Union in June 2024.[5][11]
